Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Royalty Pharma's share price for the quarter that ended in Mar. 2026 was MXN775.06. Royalty Pharma's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 444 Mil. Therefore, Royalty Pharma's market cap for the quarter that ended in Mar. 2026 was MXN343,838 Mil.
Royalty Pharma's quarterly market cap
increased
from Sep. 2025 (MXN291,738 Mil) to Dec. 2025 (MXN302,212 Mil) and
increased
from Dec. 2025 (MXN302,212 Mil) to Mar. 2026 (MXN343,838 Mil).
Royalty Pharma's annual market cap
increased
from Dec. 2023 (MXN210,839 Mil) to Dec. 2024 (MXN235,703 Mil) and
increased
from Dec. 2024 (MXN235,703 Mil) to Dec. 2025 (MXN302,212 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Royalty Pharma's Enterprise Value for Today is MXN613,345 Mil.
Royalty Pharma (MEX:RPRXN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Royalty Pharma Market Cap Related Terms
Royalty Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for Royalty Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RPRXN vs BNTX, INSM, ROIV: Market Cap Comparison
For the Biotechnology subindustry, Royalty Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Royalty Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Royalty Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (MEX:RPRXN) has a Market Cap of MXN427,303 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Royalty Pharma and its competitors. According to the industry distribution chart, Royalty Pharma ranks #12 out of 1431 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Royalty Pharma's Market Cap too high?
Royalty Pharma's current Market Cap is MXN427,303 Mil. Based on the distribution chart, Royalty Pharma ranks #12 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Market Cap compare to BNTX and INSM?
According to the Biotechnology industry distribution chart, Royalty Pharma ranks #12 out of 1431 companies for Market Cap. This places Royalty Pharma in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Royalty Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Royalty Pharma's current Market Cap is MXN427,303 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Market Cap of MXN427,303 Mil. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Market Cap is MXN427,303 Mil. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Market Cap is MXN427,303 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?
Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued.
The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.
Key valuation signals for MEX:RPRXN:
Market Cap: MXN427,303 Mil
GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score
Get the complete analysis for MEX:RPRXN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RPRXN has been successfully added to your 
